People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ultivue, Inc. | — | Biotechnology | Series B | $55.2M | $23.4M | 2017 |
Lian Yong Chen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lian Yong Chen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Crandell | 1 | 11 |
| Andrea Jackson | 1 | 6 |
| David R. Walt | 1 | 5 |
| Robert Carson | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| Peng Yin | 1 | 3 |
| Michael Natan | 1 | 3 |
| Andrew Stevenson | 1 | 2 |
| Wen R. Chen | 1 | 1 |
| Peng R. Ying | 1 | 1 |
| Sharon Yong Kedar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.